| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
The prognosis of pancreatic cancer remains very poor, the mainly reason might be the prominent resistance to chemoradiotherapy. However, the mechanism of chemoradiotherapy resistance in pancreatic cancer has not been fully understood. We aim to investigate the relationship between pancreatic cancer stem cells and chemoradiotherapy resistance, and identify the specific biomarkers, which promote tumor survival in pancreatic cancer with chemoradiotherapy.
Firstly, we transplanted human pancreatic cancer tissue into mice to construct pancreatic cancer mice model. With gemcitabine treatment, we found that the population of pancreatic cancer stem cells was increasing. Moreover, we identified expression of multiple transporters were upregulated after gemcitabine treatment with proteomic analysis, and these upregulated transporters were mainly detected in CD133+CD44+ cancer cells. Our results suggest that these transporters may exhibit important roles in the chemoradiotherapy resistance.
|
